AB0603 THE NEW POSSIBILITIES OF USING CHONDROITIN SULFATE IN PATIENTS WITH KNEE OSTEOARTHRITIS

Background: Administration of Chondroitin Sulfate for treatment osteoarthritis included types include systemic and parenteral therapies. The benefits local therapies between difference route is ambivalent. Objectives: To evaluate effectiveness safety (CS) by intramuscular concomitant (intramuscular intraarticular) administration in patients with knee (OA). Methods: In total 150 OA according ACR criteria radiological stages 2 3 to Kellgren-Lawrence were enrolled. Patients divided groups: 75 (R) received course 25 injection every other day: at the first injection’s dose 100 mg, continue 200 2nd group (N) 5 intra-articular injections target mg once per days, 16 day mg. All NSAID - meloxicam stable 15 day. checked WOMAC, pain visual analog scale (VAS), McGiIl Pain Questionnaire (MPQ). At baseline, standard clinical examination all blood tests, urine test, coagulation panel ECG. Results: After comparing two groups end intensity VAS was significantly greater R (21,88±13,24 vs 16,81±13,49; р<0,0001). There no significant differences improvement WOMAC subscales MPQ from baseline. Serious adverse events (AE) absent. 11 AE’s detected 3,3% (5/150), but 100% cases resolved course. Conclusion: CS effective decreased stiffness, improved functional ability joints both administration. However, results shows combination: lower injections. Probably, it associated faster resolution synovitis intraarticular administration, that leads choose this comorbidity. Disclosure Interests: None declared.